Leadership

Dr. Andrew W. Lo co-founded QLS Technologies in 2025. He is also the Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management, director of MIT’s Laboratory for Financial Engineering, and principal investigator at MIT’s Computer Science and Artificial Intelligence Laboratory. Prior to QLS, Dr. Lo was Chairman and Chief Investment Strategist of AlphaSimplex Group, a quantitative investment company.  His healthcare-related research interests include new financial and business models for drug and device development and healthcare delivery, statistical methods for incorporating patient preferences into the drug approval process, and predicting clinical trial outcomes via machine learning techniques. Dr. Lo is a co-founder of BridegBio Pharma, Quantile Health, and Uncommon Cures; a director of AbCellera, BridgeBio Pharma, n-Lorem Foundation, Uncommon Cures, and Vesalius; and an advisor to the American Cancer Society’s BrightEdge Impact Fund and several other biotech companies. He holds a B.A. in economics from Yale University and an A.M. and Ph.D. in economics from Harvard University.

Dr. Shomesh E. Chaudhuri co-founded QLS Technologies in 2025 and currently serves as the firm’s Chairman. Dr. Chaudhuri has developed portfolio intelligence platforms for several biopharma companies, consulting directly with CEOs, CFOs, and their staffs to help align their financing structures with their scientific and medical objectives. He has also led the development of the firm’s core analytics platform, including QLS’s machine-learning driven forecasts of clinical trial outcomes, and has overseen the implementation of the entire QLS technology infrastructure and computational architecture. Prior to QLS, Dr. Chaudhuri was a postdoctoral associate at MIT’s Sloan School of Management where he designed new funding vehicles and business models to access previously untapped pools of capital to support biomedical innovation. He has published articles in top finance and biotech journals including JAMA Oncology, the Journal of Financial Economics, and Management Science and is the co-author of the textbook Healthcare Finance: Modern Financial Analysis for Accelerating Biomedical Innovation. He holds a B.S, in engineering sciences (bioengineering) from Harvard University and an M.S. and Ph.D. in electrical engineering and computer science from MIT.

Michael Hay co-founded QLS Technologies in 2025, and currently serves as the firm’s President and Chief Business Officer. is a seasoned leader in pharmaceutical and healthcare intelligence, with two decades of experience growing, integrating, and transacting data and services companies. Michael was most recently serving as General Manager of Strategic Intelligence at Norstella in New York. Prior to his role at Norstella, he was the General Manager for the Americas at Pharma Intelligence | Informa, where he oversaw operations and strategic direction for the company’s intelligence products across the region. Michael’s earlier experience includes years as Head of Intelligence Products for Pharma Intelligence | Informa, Managing Director of Sagient/Medtrack at Informa and Executive Vice President of Sagient Research Systems. Michael’s career began with a foundational role as Manager of Capital Markets Intelligence at Thomson Financial, where he developed expertise in corporate client relationships and market analysis.

Throughout his career, he has consulted for leading pharmaceutical companies and investment firms, providing strategic insights for product development, corporate planning, and market positioning. Recognized for his deep industry knowledge and analytical acumen, Michael has played a pivotal role in shaping healthcare intelligence platforms and supporting critical investment and business decisions in the life sciences sector.

Michael is also recognized for his impactful contributions to the literature on drug development success rates and clinical trial analytics. He is the lead author of the landmark study “Clinical Development Success Rates for Investigational Drugs,” published in Nature Biotechnology in 2014, which remains a widely cited reference for benchmarking probabilities of success across therapeutic areas. His work has informed the development of predictive analytics tools for clinical trials, including Biomedtracker’s Likelihood of Approval model. Michael’s research and publications have helped shape industry understanding of R&D productivity, regulatory impacts, and risk assessment in pharmaceutical innovation.

Michael holds a Bachelor of Science in Finance and Management from the University of Colorado at Boulder.

Dr. Raven Reddy co-founded QLS Technologies in 2025 and currently serves as the firm’s Chief Product Officer. Dr. Reddy has worked at the interface of scientific, operational, and business strategy across the drug development landscape. He has developed strategies for biopharma companies and venture investors with novel business structures designed to capitalize on emergent opportunities within the biopharma ecosystem. Most recently, he worked with Curie.Bio as they scaled their seed investing and co-piloting organization. Prior to Curie, he worked with BridgeBio Pharma, which was co-founded by Andrew Lo around an innovative securitization strategy for rare disease drug development, implemented in one of the first “hub and spoke” models in the industry. Starting as Chief of Staff to Neil Kumar prior to their IPO in 2019, Dr. Reddy identified bespoke challenges along the evolution into a fully integrated commercial company and designed a portfolio of knowledge management projects in the Department of Science Operations that standardized and improved the development efficiency within focused program teams. He received his B.S. and Ph.D. in the Department of Biological Engineering from the Massachusetts Institute of Technology, where he also served as the President of the MIT Biotech Group.